Bioporto A/S logo

BIOPOR - Bioporto A/S News Story

DKK5.21 -0.2  -3.0%

Last Trade - 13/04/21

Small Cap
Market Cap £167.6m
Enterprise Value £156.3m
Revenue £2.71m
Position in Universe 759th / 1830

Completion of rights issue; total number of shares and voting rights

Wed 21st October, 2020 8:11am
For best results when printing this announcement, please click on link below:

October 21, 2020
Announcement no. 19

This announcement and the information contained herein is not for release,
publication or distribution, directly or indirectly, in or into the United
States, Canada, Australia or Japan or any jurisdiction in which such
publication or distribution is unlawful. This announcement does not constitute
or form a part of any offer to sell or solicitation of an offer to purchase or
subscribe for securities in United States, Canada, Australia or Japan or any
other jurisdiction in which it would be unlawful to do so. Any failure to
comply with this may constitute a violation of US, Canadian, Australian or
Japanese securities laws or the securities laws of other states as the case
may be. Any securities described herein may not be offered or sold in the
United States absent registration or an exemption from registration; any
public offering of securities to be made in the United States will be made by
means of a prospectus that may be obtained from the company that will contain
detailed information about the company and management, as well as financial

Completion of rights issue; total number of shares and voting rights

BioPorto A/S (“BioPorto” or the “Company”) today announces the
completion of the fully-guaranteed rights issue announced on 25 September 2020
(“the Offering”). The 66,645,476 new shares will be admitted to trading
and official listing on Nasdaq Copenhagen A/S under the Company’s permanent
ISIN-code (DK0011048619), with the expected first day of trading being 22
October 2020.

BioPorto’s share capital has been increased by DKK 66,645,476 as a result of
the completion of the Offering. Accordingly, the nominal value of the
Company’s total share capital amounts to DKK 266,581,904 divided into
266,581,904 shares each carrying 1 voting right, corresponding to a total of
266,581,904 voting rights cf. section 32 of the Danish Capital Markets Act.

The Company’s articles of association has been updated to reflect the
capital increase and are available at

For further information, please contact:
Peter Mørch Eriksen, CEO
Ole Larsen, CFO
Telephone +45 4529 0000, e-mail:

About BioPorto
BioPorto is an in vitro diagnostics company that provides tests and antibodies
to clinicians and researchers around the world. We use our antibody and assay
expertise to transform novel research tools into clinically actionable
biomarkers that can make a difference in patients’ lives. BioPorto is
headquartered in Hellerup, Denmark and is listed on the NASDAQ Copenhagen
stock exchange  CPH:BIOPOR .

Forward-looking statement disclaimer:
Certain statements in this announcement are forward-looking statements, which
are based on the Company’s expectations, intentions and projections
regarding its future performance, anticipated events or trends and other
matters that are not historical facts, including with respect to the timing,
terms and consummation of the rights issue described herein and potential FDA
clearance and commercialization of The NGAL Test. These forward-looking
statements, which may use words such as “aim”, “anticipate”,
“believe”, “intend”, “estimate”, “expect” and words of similar
meaning, include all matters that are not historical facts. These
forward-looking statements involve risks, and uncertainties that could cause
the actual results of operations, financial condition, liquidity, dividend
policy and the development of the industry in which the company’s business
operates to differ materially from the impression created by the
forward-looking statements. These statements are not guarantees of future
performance and are subject to known and unknown risks, uncertainties and
other factors that could cause actual results to differ materially from those
expressed or implied by such forward-looking statements. Given these risks and
uncertainties, prospective investors are cautioned not to place undue reliance
on forward-looking statements. Forward-looking statements speak only as of the
date of such statements and, except as required by applicable law, BioPorto
undertakes no obligation to update or revise publicly any forward-looking
statements, whether as a result of new information, future events or

*     2020 10 21 Announcement no. 19
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.